OncoMatch/Clinical Trials/NCT04965454
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
Is NCT04965454 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fluorine-18 fluorocholine for hepatocellular carcinoma non-resectable.
Treatment: Fluorine-18 fluorocholine — This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET/CT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Lab requirements
Blood counts
Deemed eligible for treatment with an immune checkpoint inhibitor agent based on ... hematologic function
Kidney function
Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula
Liver function
ALT and AST ≤7x upper limit of normal; Total bilirubin ≤4 mg/dL; Albumin ≥2.8 g/dL; Child-Pugh score of 9 or less
Child-Pugh score of 9 or less; Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula; ALT and AST ≤7x upper limit of normal; Total bilirubin ≤4 mg/dL; Albumin ≥2.8 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Queen's Medical Center · Honolulu, Hawaii
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04965454 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages